Expression of miRNA-451 and miRNA-885 in Meningiomas

In Vivo. 2023 Nov-Dec;37(6):2473-2479. doi: 10.21873/invivo.13354.

Abstract

Background/aim: Meningiomas are one of the most common intracranial tumors, accounting for 30% of the tumors of the central nervous system. MicroRNAs (miRNAs) are noncoding RNAs containing approximately 18-22 nucleotides that regulate gene expression by interfering with transcription or inhibiting translation. Recent studies have reported that miRNAs could provide information about the molecular pathogenesis of several types of tumors. This study aimed to examine the expression levels of miRNA-885 and -451 and to determine their potential roles as biomarkers in meningioma.

Materials and methods: In total, 29 patients with meningioma (9 males and 20 females) were included in this study. The expression levels of miRNA were determined using real-time polymerase chain reaction. In addition, receiver operating characteristic curve analysis was used to analyze the predictive potential of miRNAs.

Results: Our results indicated a significant increase in miRNA-451 expression levels (p=0.003); however, there was no significant change in miRNA-885 expression levels (p=0.139) in patients with meningioma compared with the control group. Moreover, miRNA-885 and miRNA-451 expression levels did not differ significantly based on the histopathological grade of meningioma.

Conclusion: miRNA-451 may be a novel potential marker for the diagnosis and prognosis, and a target for meningioma treatment.

Keywords: Meningiomas; gene expression; microRNA-451; microRNA-885; neuro-oncology.

MeSH terms

  • Biomarkers
  • Female
  • Gene Expression Profiling / methods
  • Humans
  • Male
  • Meningeal Neoplasms* / genetics
  • Meningeal Neoplasms* / metabolism
  • Meningeal Neoplasms* / pathology
  • Meningioma* / genetics
  • Meningioma* / metabolism
  • Meningioma* / pathology
  • MicroRNAs* / genetics
  • Prognosis

Substances

  • MicroRNAs
  • Biomarkers
  • MIRN885 microRNA, human